An Israeli health-tech company called IMMA Health just scored a major win with a $1.6 million grant from the Israel Innovation Authority. This funding, along with a Seal of Excellence from the European Innovation Council, supports their new at-home device that lets women do their own fertility scans using AI and robotics.
This breakthrough comes at a time when fertility treatments are in high demand worldwide. With IVF success rates hovering around 30 percent for women under 35, tools like this could make monitoring easier and more accessible, potentially helping millions of couples build families.
Breaking Down the New Device
IMMA Health is building the first self-operated transvaginal ultrasound system for home use. Women insert a small robotic probe that captures 3D images of their reproductive organs. AI software then analyzes the scans and sends reports straight to doctors.
This setup cuts down on clinic visits, which can be stressful and time-consuming during fertility treatments. Early tests show it provides clear, standardized data that helps track ovulation and follicle growth more accurately than traditional methods.
Experts say this could reduce the emotional toll of infertility. One user in a pilot study shared how it gave her peace of mind by letting her check progress without leaving home.
The device is still in development, but plans include integration with apps for real-time updates. As global fertility rates drop, with the World Health Organization reporting one in six people affected by infertility in 2025, innovations like this address a growing need.
How the Funding Came Together
The $1.6 million grant marks a big step for IMMA Health, adding to their previous raises. They had already pulled in $1.1 million from investors to kick off the project.
This latest boost from the Israel Innovation Authority focuses on advancing the tech through clinical trials. The EU’s Seal of Excellence opens doors to more European partnerships and possible additional funding.
Beatrice Chemla, the company’s CEO and co-founder, called it a game-changer. She explained that the dual support validates their goal of empowering women with control over their health data.
Funding history shows steady growth:
| Year | Amount Raised | Source |
|---|---|---|
| 2023 | $500,000 | Seed investors |
| 2024 | $600,000 | Private backers |
| 2025 | $1.6 million | Israel Innovation Authority |
This table highlights how IMMA Health has built momentum, turning early ideas into a promising product.
Why This Matters for Women’s Health
Fertility care often involves frequent ultrasounds, which can be invasive and expensive. IMMA’s device aims to change that by making scans private and convenient.
In Israel, where health-tech startups thrive, this fits into a wave of innovations. The country leads in medical advancements, with over 1,500 health startups contributing to global breakthroughs.
Worldwide, demand for IVF has surged 20 percent in the last five years, per recent industry reports. Tools that improve access could lower costs, which average $12,000 per cycle in the US.
Beyond fertility, the tech might expand to monitor conditions like endometriosis, affecting 10 percent of women. Logical next steps include adapting it for broader gynecological care.
Challenges and Future Outlook
No new tech is without hurdles. Regulatory approvals from bodies like the FDA are crucial, and IMMA Health is working toward that in 2025.
Privacy concerns come up with AI handling sensitive health data. The company promises strong encryption to protect users.
Looking ahead, partnerships with clinics could speed up adoption. Recent events, like a 2025 surge in telehealth funding, show the market is ready for at-home solutions.
Other Israeli firms are pushing similar boundaries, such as AI tools for embryo selection that boosted IVF success by 15 percent in trials last year.
- Potential benefits include reduced travel for rural patients.
- Faster doctor feedback through automated reports.
- Lower overall treatment costs for families.
Ties to Broader Fertility Trends
The global fertility tech scene is booming, with investments topping $500 million in 2025 alone. IMMA Health joins companies like those developing artificial wombs or AI sperm analysis.
A recent study from the University of Tokyo used AI to predict egg quality, aligning with IMMA’s approach. These advances tackle declining birth rates, seen in places like Japan and Europe.
In the US, new policies in 2025 expanded insurance for fertility treatments, creating more demand for affordable tech.
As IMMA Health moves forward, it could inspire more women-led startups in health tech, where female founders make up just 20 percent of the field.
What do you think about this tech? Share your thoughts in the comments and pass this article along to friends who might find it helpful.
